Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

OSE IMMUNOTHERAPEUTICS ANNOUNCES STRATEGIC AMENDMENT TO ABBVIE'S PARTNERSHIP ON ABBV-230 DEVELOPMENT STRATEGIC AMENDMENT ENHANCES OSE IMMUNOTHERAPEUTICS' ROLE IN ABBV-230 DEVELOPMENT WHILE PRESERVING ABBVIE'S LONG-TERM COMMITMENT NANTES, FRANCE, DECEMBER 8 TH , 2025  7:30AM CET - OSE IMMUNOTHERAPEUTICS SA (ISIN: FR0012127173; MNEMO: OSE) TODAY ANNOUNCED AN AMENDMENT TO ITS PARTNERSHIP AGREEMENT WITH ABBVIE REGARDING ABBV-230, A MONOCLONAL ANTIBODY DESIGNED TO RESOLVE CHRONIC AND SEVERE INFLAMMATION, CURRENTLY IN THE PRE-CLINICAL DEVELOPMENT STAGE. UNDER THE REVISED AGREEMENT, OSE IMMUNOTHERAPEUTICS REGAINS CONTROL OF THE EARLY-STAGE DEVELOPMENT OF THE ABBV-230, WHILE ABBVIE MAINTAINS ITS RIGHTS TO CONTROL FUTURE DEVELOPMENT AND COMMERCIALIZATION FOLLOWING SUCCESSFUL COMPLETION OF PHASE 1.

OSE IMMUNOTHERAPEUTICS ANNOUNCES STRATEGIC AMENDMENT TO ABBVIE'S PARTNERSHIP ON ABBV-230 DEVELOPMENT

DATA BEING PRESENTED SHOWCASES ABBVIE'S BREADTH AND DEPTH OF RESEARCH ACROSS A RANGE OF THERAPEUTIC MODALITIES SUCH AS T-CELL ENGAGERS, BCL-2 INHIBITORS AND ANTIBODY-DRUG CONJUGATES FOR A SPECTRUM OF DIFFICULT-TO-TREAT BLOOD CANCERS NORTH CHICAGO, ILL. , DEC. 2, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED IT WILL UNVEIL NEW DATA AT THE 2025 AMERICAN SOCIETY OF HEMATOLOGY (ASH) CONGRESS, SHOWCASING CONTINUED ADVANCES IN RESEARCH ACROSS MULTIPLE BLOOD CANCERS INCLUDING  MULTIPLE MYELOMA (MM), FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), ACUTE MYELOID LEUKEMIA (AML) AND AMYLOIDOSIS (AL).

ABBVIE TO FEATURE NEW DATA AT ASH 2025 SHOWCASING CONTINUED ADVANCES ACROSS NOVEL TREATMENT MODALITIES IN MULTIPLE BLOOD CANCERS

MONTREAL, NOV. 28, 2025 (GLOBE NEWSWIRE) -- TODAY, ABBVIE (NYSE: ABBV) HAS ANNOUNCED TWO POSITIVE UPDATES FOR CANADIANS LIVING WITH ULCERATIVE COLITIS (UC).

SKYRIZI (RISANKIZUMAB) RECEIVES POSITIVE REIMBURSEMENT RECOMMENDATION BY CANADA'S DRUG AGENCY FOR ULCERATIVE COLITIS AND ABBVIE CONCLUDES LETTER OF INTENT WITH THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE

MONTREAL, NOV. 25, 2025 (GLOBE NEWSWIRE) -- TODAY, ABBVIE (NYSE: ABBV), JOINTLY WITH THE ADMARE BIOINNOVATIONS, ANNOUNCED THE LAUNCH OF THE ABBVIE BIOTECH INNOVATORS AWARD, A PRIZE TO HELP FOSTER INNOVATION AND SUPPORT GROWTH IN QUEBEC'S LIFE SCIENCES SECTOR.

ABBVIE AND ADMARE BIOINNOVATIONS FOSTER LIFE SCIENCES INNOVATION WITH THE LAUNCH OF THE ABBVIE BIOTECH INNOVATORS AWARD IN QUEBEC

NORTH CHICAGO, ILL. , NOV. 24, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL PARTICIPATE IN THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE ON WEDNESDAY, DECEMBER 3, 2025.

ABBVIE TO PRESENT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

- EPKINLY PLUS RITUXIMAB AND LENALIDOMIDE (EPKINLY + R2) IS NOW THE FIRST AND ONLY BISPECIFIC ANTIBODY COMBINATION THERAPY AVAILABLE FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY - IN THE PHASE 3 EPCORE FL-1 TRIAL, EPKINLY + R2 DEMONSTRATED SIGNIFICANTLY SUPERIOR PROGRESSION-FREE SURVIVAL AND OVERALL RESPONSE RATES COMPARED TO STANDARD OF CARE R2 WITH APPROXIMATELY 3 OUT OF 4 PATIENTS ACHIEVING A COMPLETE RESPONSE - APPROVAL MARKS THIRD INDICATION FOR EPKINLY AND FIRST-EVER FDA APPROVAL FOR A BISPECIFIC COMBINATION THERAPY IN LYMPHOMA NORTH CHICAGO, ILL. , NOV. 18, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT EPKINLY (EPCORITAMAB-BYSP), A T-CELL ENGAGING BISPECIFIC ANTIBODY ADMINISTERED SUBCUTANEOUSLY, IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (EPKINLY + R2) IS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL).

ABBVIE ANNOUNCES U.S. FDA APPROVAL OF EPKINLY (EPCORITAMAB-BYSP) IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

AS A LEADER IN MIGRAINE TREATMENT, ABBVIE IS COMMITTED TO ADDRESSING THE IMPACT OF MIGRAINE IN THE WORKPLACE. 2025 HONOREES REPRESENT A DIVERSE GROUP OF ACHIEVERSFROM TEACHERS AND AUTHORS TO SMALL BUSINESS OWNERS AND ASPIRING YOGA AND MEDITATION INSTRUCTORSEACH REDEFINING SUCCESS WHILE LIVING WITH MIGRAINE.

ABBVIE ANNOUNCES 20 RECIPIENTS OF MIGRAINE CAREER CATALYST AWARD

-A TOTAL OF 17 ABSTRACTS, INCLUDING THREE ACCEPTED FOR PRESENTATION IN THE COSMETIC "TOP TEN" SESSION, UNDERSCORE ALLERGAN AESTHETICS' GLOBAL INDUSTRY LEADERSHIP ACROSS MULTIPLE AESTHETIC CATEGORIES -ORAL ABSTRACT PRESENTATIONS INCLUDE PHASE 3 CLINICAL STUDY RESULTS FOR FIRST-IN-CLASS BOTULINUM NEUROTOXIN SEROTYPE E(TRENIBOTULINUMTOXINE) AND RESULTS FROM A PHASE 4 STUDY EVALUATING NATURAL OUTCOMES AND PATIENT SATISFACTION IN A DIVERSE POPULATION FOLLOWING USE OF 64 UNITS OF BOTOXCOSMETIC (ONABOTULINUMTOXINA) FOR TREATMENT OF UPPER FACIAL LINES - EXPERT PANEL DISCUSSION EXPLORES NEW HYALURONIC ACID INJECTABLE FILLERS REPORT, ALONG WITH CURRENT USE, FACTS, AND REAL-WORLD SATISFACTION DATA IRVINE, CALIF. , NOV. 12, 2025 /PRNEWSWIRE/ --ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED IT WILL PRESENT DATA HIGHLIGHTING EFFICACY, SAFETY AND PATIENT-REPORTED OUTCOMES ACROSS ITS PORTFOLIO DURING THE 2025 AMERICAN SOCIETY OF DERMATOLOGIC SURGERY (ASDS) ANNUAL MEETING, NOVEMBER 13-16, 2025, IN CHICAGO, ILLINOIS.

ALLERGAN AESTHETICS UNVEILS NEW DATA AT 2025 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ANNUAL MEETING SHOWCASING TRANSFORMATIVE INNOVATION AND PORTFOLIO EXCELLENCE

PARMA, ITALY, NOV. 12, 2025 (GLOBE NEWSWIRE) -- CHIESI GROUP TODAY ANNOUNCED IT HAS ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH ALIADA THERAPEUTICS, A WHOLLY OWNED SUBSIDIARY OF ABBVIE, TO ADVANCE BLOOD-BRAIN BARRIER (BBB)-CROSSING PLATFORM TECHNOLOGY IN LYSOSOMAL STORAGE DISORDERS (LSD) TO ADDRESS CHALLENGING DISEASE AREAS WITH HIGH UNMET NEED.

CHIESI GROUP ENTERS INTO AN EXCLUSIVE LICENSE AGREEMENT WITH ALIADA THERAPEUTICS, A WHOLLY OWNED SUBSIDIARY OF ABBVIE, TO ADVANCE BLOOD-BRAIN BARRIER-CROSSING PLATFORM TECHNOLOGY IN LYSOSOMAL STORAGE DISORDERS

REPORTS THIRD-QUARTER DILUTED EPS OF $0.10 ON A GAAP BASIS, A DECREASE OF 88.6 PERCENT; ADJUSTED DILUTED EPS OF $1.86, A DECREASE OF 38.0 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $1.50 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE  DELIVERS THIRD-QUARTER NET REVENUES OF $15.776 BILLION, AN INCREASE OF 9.1 PERCENT ON A REPORTED BASIS OR 8.4 PERCENT ON AN OPERATIONAL BASIS  THIRD -QUARTER GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $7.885 BILLION, AN INCREASE OF 11.9 PERCENT ON A REPORTED BASIS, OR 11.2 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $4.708 BILLION; GLOBAL RINVOQ NET REVENUES WERE $2.184 BILLION; GLOBAL HUMIRA NET REVENUES WERE $993 MILLION  THIRD -QUARTER GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $2.841 BILLION, AN INCREASE OF 20.2 PERCENT ON A REPORTED BASIS, OR 19.6 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $934 MILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $985 MILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $642 MILLION  THIRD -QUARTER GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $1.682 BILLION, A DECREASE OF 0.3 PERCENT ON A REPORTED BASIS, OR 1.3 PERCENT ON AN OPERATIONAL BASIS; GLOBAL IMBRUVICA NET REVENUES WERE $706 MILLION; GLOBAL VENCLEXTA NET REVENUES WERE $726 MILLION; GLOBAL ELAHERE NET REVENUES WERE $170 MILLION  THIRD -QUARTER GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $1.193 BILLION, A DECREASE OF 3.7 PERCENT ON A REPORTED BASIS, OR 4.2 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $637 MILLION; GLOBAL JUVEDERM NET REVENUES WERE $253 MILLION  RAISES 2025 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $10.38 - $10.58 TO $10.61 - $10.65, WHICH INCLUDES AN UNFAVORABLE IMPACT OF $2.05 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE INCURRED YEAR-TO-DATE THROUGH THE THIRD QUARTER 2025  ANNOUNCES 2026 DIVIDEND INCREASE OF 5.5 PERCENT, BEGINNING WITH DIVIDEND PAYABLE IN FEBRU

ABBVIE REPORTS THIRD-QUARTER 2025 FINANCIAL RESULTS

ALLERGAN AESTHETICS GIVES PATIENTS EXCITING BOTOX COSMETIC OFFERS ONLY IN THE ALL APP BUY ONE $50 GIFT CARD, GET ONE FREE, PLUS, REGISTER, BOOK A CONSULTATION, AND GET TREATED FOR A CHANCE TO WIN $25,000*  IRVINE, CALIF. , OCT. 29, 2025 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED THE SEVENTH ANNUAL BOTOX COSMETIC DAYWILL TAKE PLACE ON WEDNESDAY, NOVEMBER 19, 2025.

THE ONE & ONLY BOTOX COSMETIC (ONABOTULINUMTOXINA) DAY RETURNS NOVEMBER 19 WITH THE BIGGEST CELEBRATION OF THE YEAR

IN TWO REPLICATE PHASE 3 STUDIES, UPADACITINIB (RINVOQ  ) ACHIEVED THE CO-PRIMARY ENDPOINTS OF 50% REDUCTION IN TOTAL VITILIGO AREA SCORING INDEX (T-VASI 50) FROM BASELINE AND 75% REDUCTION IN FACIAL VITILIGO AREA SCORING INDEX (F-VASI 75) FROM BASELINE AT WEEK 481 BOTH STUDIES MET KEY RANKED SECONDARY ENDPOINTS1 NORTH CHICAGO, ILL. , OCT. 29, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCEDPOSITIVE TOPLINE RESULTS FROM TWO REPLICATE PHASE 3 STUDIES EVALUATING THE SAFETY AND EFFICACY OF UPADACITINIB (RINVOQ;15 MG, ONCE DAILY IN ADULT AND ADOLESCENT PATIENTS LIVING WITH NON-SEGMENTAL VITILIGO (NSV).1 NSV, THE MOST COMMON FORM OF VITILIGO (OCCURRING IN OVER 90% OF PATIENTS), IS CHARACTERIZED BY SYMMETRICAL AND BILATERAL WHITE PATCHES ON BOTH SIDES OF THE BODY.2-4 "VITILIGO IS MORE THAN A SKIN CONDITION  IT'S A CHRONIC AUTOIMMUNE DISEASE THAT CAN DEEPLY AFFECT A PERSON'S CONFIDENCE, IDENTITY AND DAILY LIFE,"SAID KORI WALLACE, M.D.

ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 PIVOTAL STUDIES EVALUATING UPADACITINIB (RINVOQ) IN ADULTS AND ADOLESCENTS WITH VITILIGO

EACH WINNER WILL BE AWARDED A $20,000 GRANT TO FUEL THEIR BUSINESSES. SINCE THE PROGRAM'S INCEPTION, BOTOX COSMETIC HAS AWARDED MORE THAN $1 MILLION IN GRANTS TO THE CONFIDENCE PROJECT ENTREPRENEURS.

THE CONFIDENCE PROJECT BY BOTOX COSMETIC (ONABOTULINUMTOXINA) UNVEILS THIS YEAR'S GRANT RECIPIENTS

UPADACITINIB DEMONSTRATED SUPERIORITY VERSUS ADALIMUMAB FOR PRIMARY ENDPOINT OF ACHIEVING LOW DISEASE ACTIVITY (DAS28-CRP3.2) AND RANKED SECONDARY ENDPOINT OF REMISSION(DAS28-CRP

RINVOQ (UPADACITINIB) DEMONSTRATED SUPERIORITY VERSUS HUMIRA (ADALIMUMAB) FOR PRIMARY ENDPOINT IN A HEAD-TO-HEAD STUDY IN RHEUMATOID ARTHRITIS PATIENTS WHO HAVE FAILED FIRST TNF INHIBITOR

ACQUISITION EXPANDSABBVIE'S PSYCHIATRY PIPELINE WITH THE ADDITION OF A NEXT-GENERATION PSYCHEDELIC COMPOUND CURRENTLY IN PHASE 2 DEVELOPMENT FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD). NORTH CHICAGO, ILL.

ABBVIE COMPLETES ACQUISITION OF GILGAMESH PHARMACEUTICALS' BRETISILOCIN

CAMBRIDGE, MASS.--(BUSINESS WIRE)--ENVERIC BIOSCIENCES (NASDAQ: ENVB) (ENVERIC OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING NEXT-GENERATION NEUROPLASTOGENIC SMALL MOLECULES TO ADDRESS PSYCHIATRIC AND NEUROLOGICAL DISORDERS, TODAY ANNOUNCED THAT IT HAS HIRED INTELLECTUAL PROPERTY POWERHOUSE FISH AND RICHARDSON P.C. TO CONTEST A POST-GRANT REVIEW (PGR) PETITION FILED BY GILGAMESH PHARMACEUTICALS (GILGAMESH) AGAINST ENVERIC'S ISSUED U.S. PATENT NO. 12,138,276 (THE'276 PATENT,) ENTITLED,.

ENVERIC BIOSCIENCES HIRES IP POWERHOUSE TO DEFEND ITS U.S. PATENT WITH CLAIMS RELEVANT TO BRETISILOCIN, RECENTLY ACQUIRED BY ABBVIE IN $1.2 BILLION DEAL

-    UPDATED INDICATION ALLOWS THE USE OF RINVOQ (UPADACITINIB) PRIOR TO THE USE OF TUMOR NECROSIS FACTOR (TNF) BLOCKING AGENTS IN PATIENTS FOR WHOM USE OF THESE TREATMENTS IS CLINICALLY INADVISABLE AND WHO HAVE RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY NORTH CHICAGO, ILL. , OCT. 13, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) THAT UPDATES THE INDICATION STATEMENT FOR RINVOQ (UPADACITINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD).

U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES UPDATED INDICATION STATEMENT FOR RINVOQ (UPADACITINIB) FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

NEW DATA FROMTELISOTUZUMAB ADIZUTECAN (TEMAB-A) AND ABBV-706 ACROSS PANCREATIC, COLORECTAL, AND SOLID TUMORS, HIGHLIGHT PROGRESS IN ABBVIE'S GROWING ADC PORTFOLIO DESIGNED TO TARGET DIFFICULT-TO-TREAT CANCERS. NORTH CHICAGO, ILL.

ABBVIE TO PRESENT NEW DATA AT ESMO 2025 REINFORCING LEADERSHIP IN ADVANCING TARGETED THERAPIES FOR SOLID TUMORS

BY THE MAKERS OF BOTOX COSMETIC (ONABOTULINUMTOXINA), SKINMEDICA'S NEW PACKAGING FEATURES A REFRESHED LOGO, MODERNIZED LOOK, AND LUXE COPPER COLOR PALETTE. THE BRAND'S NEW HA5 MOISTURIZER IS DESIGNED TO SUPPORT THE SKIN BARRIER AND MICROBIOME FOR BOUNCY, DEWY, AND SOFT SKIN.

AbbVie Inc.

ABBV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ABBV